ErbB/BTK inhibitors

US11007198B2 · kind B2 · utility

Assignee

• Dizal (Jiangsu) Pharmaceutical Co., Ltd. · CN

Inventors

• Zhengtao LI · Shanghai, CN
• Hao ZOU · Nanhu, CN
• Wei Zhu · Shanghai, CN
• Changmao Shen · Shanghai, CN
• Rumin WANG · Shanghai, CN
• Wengeng LIU · Shanghai, CN
• Xiang Chen · 安丰镇, CN
• Honchung Tsui · Shanghai, CN
• Zhenfan Yang · Shanghai, CN
• Xiaolin Zhang · Singapore, SG

Key dates

• Filing date: Jun 24, 2020
• Grant date: May 18, 2021
• Expiry date: Jun 24, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.